Trump Set to Sign One of the Most Important Executive Orders in U.S. History
Former President Donald Trump has announced plans to sign what he calls one of the most significant executive actions in U.S. history.
The sweeping order is aimed at slashing the cost of prescription drugs for American consumers. The signing is scheduled for tomorrow morning at 9:00 a.m. at the White House.
In a post on Truth Social, Trump addressed the long-standing issue of high pharmaceutical prices in the United States, calling it an embarrassment that American patients often pay five to ten times more than individuals in other countries for identical medications produced by the same manufacturers.
Trump argued that the pharmaceutical industry’s justification — primarily citing research and development expenses — has unfairly placed the financial burden on American citizens. He also pointed to the role of campaign contributions in keeping drug prices elevated, stating that political influence had long shielded the industry from reforms.
READ MORE:
Best Presale Crypto Projects You Can’t Ignore: BlockDAG, Dragoin, Web3 ai & More Heating Up in 2025
However, he emphasized that this would no longer be the case under his leadership or with the support of the Republican Party. Trump’s proposed solution centers around a “Most Favored Nation” pricing policy, which would ensure the United States pays no more for a drug than the lowest price paid by any other country. According to him, this approach could result in price reductions ranging from 30% to 80%, with the effects taking place almost immediately.
In addition to lowering consumer costs, Trump claimed the policy would lead to a massive reduction in federal healthcare spending, saving the U.S. government trillions of dollars over time. The move, he said, would not only restore fairness for American patients but also shift global pharmaceutical pricing dynamics.
“This is about putting American patients first,” Trump declared. “For the first time in years, we’re leveling the playing field.”
The executive order, if implemented as described, could mark a major shift in how the U.S. government negotiates and regulates drug pricing — an issue that has long sparked bipartisan debate but seen limited structural change.
Alexander Stefanov
Reporter at Coindoo
Alex is an experienced finance journalist and a cryptocurrency and blockchain enthusiast. With over 8 years of experience covering the crypto, blockchain and fintech industries, he deeply understands the complex and constantly evolving world of digital assets. His insightful and thought-provoking articles provide readers with a clear picture of the latest developments and trends in the market. His passionate approach allows him to break down complex ideas into accessible and insightful content. Follow up on his content to be up to date with the most important trends and topics.
